BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance
出版年份 2020 全文链接
标题
BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance
作者
关键词
-
出版物
Cancers
Volume 13, Issue 1, Pages 78
出版商
MDPI AG
发表日期
2020-12-30
DOI
10.3390/cancers13010078
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer
- (2020) Simona D’Aguanno et al. Cells
- STAT3 enhances the constitutive activity of AGC kinases in melanoma by transactivating PDK1
- (2019) María Elisa Picco et al. Cell and Bioscience
- BCL-2 family isoforms in apoptosis and cancer
- (2019) Chloe F. A. Warren et al. Cell Death & Disease
- Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma
- (2019) Kalle E. Mattila et al. ACTA ONCOLOGICA
- An Autocrine Wnt5a Loop Promotes NF-κB Pathway Activation and Cytokine/Chemokine Secretion in Melanoma
- (2019) Gastón Barbero et al. Cells
- Bcl2l10 mediates the proliferation, invasion and migration of ovarian cancer cells
- (2019) Su‑Yeon Lee et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10
- (2018) Adrien Nougarede et al. CANCER RESEARCH
- Targeting BCL-2 regulated apoptosis in cancer
- (2018) Kirsteen J. Campbell et al. Open Biology
- Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs
- (2018) Elena Makino et al. Cell Death & Disease
- Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF -mutated melanoma and other advanced malignancies
- (2018) Minny Bhatty et al. CANCER
- Activated Stat-3 in Melanoma
- (2017) Jane L. Messina et al. Cancer Control
- Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling
- (2016) Jasmina Paluncic et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice
- (2016) Mohamed-Amine Hamouda et al. JOURNAL OF EXPERIMENTAL MEDICINE
- BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo
- (2016) Yun Bai et al. MOLECULAR CARCINOGENESIS
- The Comparison of MTT and CVS Assays for the Assessment of Anticancer Agent Interactions
- (2016) Lidia Śliwka et al. PLoS One
- Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells
- (2015) Nabanita Mukherjee et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Filamin A Expression Negatively Regulates Sphingosine-1-Phosphate-Induced NF-κB Activation in Melanoma Cells by Inhibition of Akt Signaling
- (2015) Ludmila Campos et al. MOLECULAR AND CELLULAR BIOLOGY
- ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K/Akt pathway
- (2015) Natalia Brenda Fernández et al. MOLECULAR CARCINOGENESIS
- The Expression of p-STAT3 in Stage IV Melanoma: Risk of CNS Metastasis and Survival
- (2015) Ian Lee et al. Oncotarget
- BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
- (2015) Thomas Cluzeau et al. Oncotarget
- The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G1cell-cycle arrest and not a direct effect on BIK protein stability
- (2014) Matthew J. Sale et al. BIOCHEMICAL JOURNAL
- Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival
- (2014) Joshua M. Eichhorn et al. EXPERIMENTAL CELL RESEARCH
- TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein
- (2014) Sanchita Bhatnagar et al. NATURE
- Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance
- (2014) M N Serasinghe et al. ONCOGENE
- The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
- (2014) P Geserick et al. Cell Death & Disease
- That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance
- (2013) Matthew J Sale et al. BRITISH JOURNAL OF PHARMACOLOGY
- Anti-apoptotic proteins on guard of melanoma cell survival
- (2013) Mariusz L. Hartman et al. CANCER LETTERS
- Historical review of melanoma treatment and outcomes
- (2013) Carrie Lee et al. CLINICS IN DERMATOLOGY
- Mechanisms of Action of Bcl-2 Family Proteins
- (2013) A. Shamas-Din et al. Cold Spring Harbor Perspectives in Biology
- Mcl-1 Phosphorylation Defines ABT-737 Resistance That Can Be Overcome by Increased NOXA Expression in Leukemic B cells
- (2012) S. Mazumder et al. CANCER RESEARCH
- The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance
- (2012) D. Wroblewski et al. CARCINOGENESIS
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Cell Cycle Gene Networks Are Associated with Melanoma Prognosis
- (2012) Li Wang et al. PLoS One
- Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1
- (2012) L. J. Beverly et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
- (2012) R W Rooswinkel et al. Cell Death & Disease
- Characterization of Unique Signature Sequences in the Divergent Maternal Protein Bcl2l10
- (2011) Y. Guillemin et al. MOLECULAR BIOLOGY AND EVOLUTION
- ABT-737 synergizes with Bortezomib to kill melanoma cells
- (2011) S. N. Reuland et al. Biology Open
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
- (2010) D. Yecies et al. BLOOD
- Loss of BCL2L10 protein expression as prognostic predictor for poor clinical outcome in gastric carcinoma
- (2010) Jing Da Xu et al. HISTOPATHOLOGY
- BCL2L10 protein regulates apoptosis/proliferation through differential pathways in gastric cancer cells
- (2010) Jing Da Xu et al. JOURNAL OF PATHOLOGY
- Analysis of genome-wide methylation and gene expression induced by 5-aza-2′-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia
- (2010) Emiliano Fabiani et al. LEUKEMIA & LYMPHOMA
- BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer
- (2010) Imazeki ONCOLOGY REPORTS
- The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand
- (2010) Nai-Ying Yang et al. Pigment Cell & Melanoma Research
- A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy
- (2010) W J Placzek et al. Cell Death & Disease
- Prediction and Experimental Validation of Novel STAT3 Target Genes in Human Cancer Cells
- (2009) Young Min Oh et al. PLoS One
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Bcl-B Expression in Human Epithelial and Nonepithelial Malignancies
- (2008) M. Krajewska et al. CLINICAL CANCER RESEARCH
- Expression and Function of Bcl-2 Proteins in Melanoma
- (2008) Jurgen Eberle et al. CURRENT GENOMICS
- Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
- (2008) Mark S. Cragg et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide
- (2008) Tobias Sinnberg et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Understanding Signaling Cascades in Melanoma
- (2008) Pablo Lopez-Bergami et al. PHOTOCHEMISTRY AND PHOTOBIOLOGY
- Requirements for PKC-augmented JNK activation by MKK4/7
- (2007) Pablo Lopez-Bergami et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search